Recent Advances in the Design and Development of Non‐nucleoside Reverse Transcriptase Inhibitor Scaffolds

Pouria Shirvani; Afshin Fassihi; Lotfollah Saghaie

doi:10.1002/cmdc.201800577

journal article Dec 06, 2018

Recent Advances in the Design and Development of Non‐nucleoside Reverse Transcriptase Inhibitor Scaffolds

Pouria Shirvani Afshin Fassihi

Lotfollah Saghaie

ChemMedChem Vol. 14 No. 1 pp. 52-77 · Wiley

View at Publisher Save 10.1002/cmdc.201800577

Abstract

AbstractNon‐nucleoside reverse transcriptase inhibitors (NNRTIs) have always been an important part of the anti‐HIV‐1 combination therapy known as combination antiretroviral therapy (cART) since 1996. The use of NNRTIs for about 22 years has led to some mutations in the residues that compose the reverse transcriptase active site, resulting in the emergence of drug‐resistant viruses. Thus, the search for new potent NNRTIs with an improved safety profile and activity against drug‐resistant HIV strains is indispensable, and many hit and lead NNRTIs have been discovered in the last decade. This review provides an overview of the development in this field from 2013 to August 2018.

Topics

No keywords indexed for this article. Browse by subject →

References

166

[1]

UNAIDS Report on the Global Aids Epidemic:http://www.unaids.org/en/resources/documents/2017/2017_data_book July 20 2017.

[2]

Günthard H. F. JAMA (2016) 10.1001/jama.2016.8900

[3]

[4]

Martins S. Curr. Med. Chem. (2008) 10.2174/092986708784221467

[5]

Margolis D. M. Curr. Opin. HIV AIDS (2013) 10.1097/coh.0b013e32835ef089

[6]

Mehellou Y. J. Med. Chem. (2010) 10.1021/jm900492g

[7]

[8]

Hauser A. PLoS One (2012) 10.1371/journal.pone.0032055

[9]

Iyidogan P. Viruses (2014) 10.3390/v6104095

[10]

Zhang H. Chem. Biol. Drug Des. (2011) 10.1111/j.1747-0285.2011.01163.x

[11]

Li D. J. Med. Chem. (2012) 10.1021/jm200990c

[12]

[13]

Das K. Curr. Opin. Virol. (2013) 10.1016/j.coviro.2013.03.012

[14]

Das K. Curr. Opin. Virol. (2013) 10.1016/j.coviro.2013.03.014

[15]

[16]

Huang B. Eur. J. Med. Chem. (2015) 10.1016/j.ejmech.2015.02.022

[17]

Li X. Eur. J. Med. Chem. (2014) 10.1016/j.ejmech.2014.04.036

[18]

Zhan P. Med. Res. Rev. (2013) 10.1002/med.20241

[19]

[20]

Adams J. Ann. Pharmacother. (2010) 10.1345/aph.1m359

[21]

Alcaro S. Drug Resist. Updates (2011) 10.1016/j.drup.2011.01.002

[22]

de Béthune M. P. Antiviral Res. (2010) 10.1016/j.antiviral.2009.09.008

[23]

Jayaweera D. Expert Opin. Pharmacother. (2012) 10.1517/14656566.2012.742506

[24]

La Regina G. Antiviral Chem. Chemother. (2010) 10.3851/imp1607

[25]

Reynolds C. Chem. Soc. Rev. (2012) 10.1039/c2cs35058k

[26]

Li X. Expert Opin. Ther. Pat. (2014) 10.1517/13543776.2014.964685

[27]

Song Y. Curr. Med. Chem. (2014) 10.2174/09298673113206660298

[28]

Zhan P. Curr. Med. Chem. (2009) 10.2174/092986709788803231

[29]

[30]

Lansdon E. B. J. Med. Chem. (2010) 10.1021/jm1002233

[31]

Rawal R. K. Curr. Med. Chem. (2012) 10.2174/092986712803833326

[32]

[33]

Casado J. L. AIDS Res. Hum. Retroviruses (2002) 10.1089/08892220260139503

[34]

Esté J. A. Antiviral Res. (2010) 10.1016/j.antiviral.2009.10.007

[35]

Menéndez-Arias L. Antiviral Res. (2013) 10.1016/j.antiviral.2013.01.007

[36]

[37]

Sarafianos S. G. J. Mol. Biol. (2009) 10.1016/j.jmb.2008.10.071

[38]

Sweeney Z. K. Curr. Opin. Drug Discov. Devel. (2008)

[39]

Schrijvers R. Expert Opin. Pharmacother. (2013) 10.1517/14656566.2013.787411

[40]

Croxtall J. D. Drugs (2012) 10.2165/11209110-000000000-00000

[41]

Schafer J. J. Antiviral Ther. (2012) 10.3851/imp2254

[42]

[43]

Chen W. Eur. J. Med. Chem. (2016) 10.1016/j.ejmech.2016.05.054

[44]

Zhan P. J. Med. Chem. (2016) 10.1021/acs.jmedchem.5b00497

[45]

Xuwang C. Curr. Med. Chem. (2011) 10.2174/092986711794839142

[46]

Mingyan Y. Curr. Med. Chem. (2011) 10.2174/092986711795843209

[47]

[48]

Chen X. Curr. Pharm. Des. (2013) 10.2174/1381612811319150018

[49]

Tian Y. Curr. Med. Chem. (2012) 10.2174/092986712800167383

[50]

Zhao H. Drug Discovery Today (2009) 10.1016/j.drudis.2009.02.008

Showing 50 of 166 references

Metrics

22

Citations

166

References

Details

Published: Dec 06, 2018
Vol/Issue: 14(1)
Pages: 52-77
License: View

Authors

P

Pouria Shirvani

Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Science Isfahan University of Medical Science Hezar Jerib Avenue 81746-73461 Isfahan Iran

A

Afshin Fassihi

Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Science Isfahan University of Medical Science Hezar Jerib Avenue 81746-73461 Isfahan Iran

L

Lotfollah Saghaie

Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Science Isfahan University of Medical Science Hezar Jerib Avenue 81746-73461 Isfahan Iran

Cite This Article

Pouria Shirvani, Afshin Fassihi, Lotfollah Saghaie (2018). Recent Advances in the Design and Development of Non‐nucleoside Reverse Transcriptase Inhibitor Scaffolds. ChemMedChem, 14(1), 52-77. https://doi.org/10.1002/cmdc.201800577

Recent Advances in the Design and Development of Non‐nucleoside Reverse Transcriptase Inhibitor Scaffolds

You May Also Like